Application Nr Approved Date Route Status External Links
ANDA210158 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Dalfampridine Extended-Release Tablet Is Indicated As A Treatment To Improve Walking In Adult Patients With Multiple Sclerosis (Ms). This Was Demonstrated By An Increase In Walking Speed [See Clinical Studies (14) ]. Dalfampridine Extended-Release Tablet Is A Potassium Channel Blocker Indicated To Improve Walking In Adult Patients With Multiple Sclerosis (Ms). This Was Demonstrated By An Increase In Walking Speed (1, 14) .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Dalfampridine DALFAMPRIDINE ZINC599985

Comments